Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.

NCT03544905 is registered in ClinicalTrials.gov with Haihe Biopharma Co., Ltd. as lead sponsor.

NCT NCT03544905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03544905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.
Lead sponsor
Haihe Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 5, 2018
Completion date
December 4, 2024
Enrollment
206 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors